Peptide therapeutics firm Rhythm gets $8m from Pfizer Venture Investments
Rhythm, a Boston biotechnology company developing peptide therapeutics to treat such metabolic diseases as obesity and diabetes, said it has raised $8 million from Pfizer Venture Intestments, the venture capital arm of the drug company Pfizer and a new investor in Rhythm. That additional $8 million completes a $33 million Series B financing. The round had participation from existing investors MPM Capital, New Enterprise Associates, Third Rock Ventures, and Ipsen. This additional financing brings the total capital raised by Rhythm to $73 million.